��������

Hiroshi Nomura has served as a Director of Roivant since 2022. Mr. Nomura has served as President and Chief Executive Officer and Representative Director of Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), a pharmaceutical company based in Japan, since April 2018. Before serving at his current position, Mr. Nomura also served in a number of executive leadership roles at Sumitomo Pharma, including as a member of the Board of Directors, Senior Executive Officer, Chief Finance Officer and Representative Director between April 2017 and April 2018, and as a member of the Board of Directors, Senior Executive Officer and Chief Finance Officer from April 2014 to April 2017. Before that, Mr. Nomura also held various other positions with increasing responsibilities at Sumitomo Pharma from October 2005 to April 2014. Mr. Nomura currently serves on the boards of directors of Myovant Sciences, Sumitomo Pharma, Sumitovant Biopharma and Sumitomo Pharma Oncology, Inc. Mr. Nomura received an economics degree from University of Tokyo.